Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Mycophenolic acid (HB3987)
Description:Inosine monophosphatase dehydrogenase inhibitor
Purity:>98%
Oseltamivir phosphate (HB7776)
Description:Antiviral compound. Influenza viral neuraminidase inhibitor.
Purity:>98%
Ouabain (HB1140)
Description:Selective Na+ / K+ ATPase inhibitor. Shows antiviral activity.
Purity:>98%
Remdesivir (HB9521)
Description:Adenosine triphosphate analog with broad-spectrum antiviral activity
Purity:>98%